HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.

The leukemia from which the human cell line HL-60 was derived was classified in 1976 as acute progranulocytic leukemia (APL), although it was recognized to show a number of atypical features. In the ensuing 10 years, the concept of APL and its integral association with t(15;17) has evolved, and the concept of APL as a morphologically recognizable entity has become embodied in the term French-American-British classification M3 (FAB-M3). It is now recognized that not every case of leukemia with a high proportion of progranulocytes can be classified as FAB-M3. We reviewed the light and ultrastructural morphology of the original diagnostic material from this case, and we report that the leukemia from which HL-60 was derived does not conform to the currently recognized entity of FAB-M3 and is more appropriately classified as an acute myeloblastic leukemia with maturation, FAB-M2.

[1]  S. Collins,et al.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia , 1979 .

[2]  H. Gralnick,et al.  A VARIANT FORM OF HYPERGRANULAR PROMYELOCYTIC LEUKAEMIA (M3) , 1980, British journal of haematology.

[3]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.

[4]  S. Collins,et al.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Rowley,et al.  Hypergranular promyelocytic leukemia (APL): cytogenetic and ultrastructural specificity. , 1978, Blood.

[6]  C. Bloomfield,et al.  Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant , 1982, British journal of haematology.

[7]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Weinberg,et al.  The HL-60 transforming sequence: A ras oncogene coexisting with altered myc genes in hematopoietic tumors , 1983, Cell.

[9]  J. Strickler,et al.  Molecular cloning of the complementary DNA for human tumor necrosis factor. , 1985, Science.

[10]  J. Rowley,et al.  "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. , 1980, Blood.

[11]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[12]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[13]  R. Savage,et al.  Morphology and cytochemistry of "microgranular" acute promyelocytic leukemia (FAB M3m). , 1981, American journal of clinical pathology.

[14]  R. Gallo,et al.  onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient , 1982, Nature.

[15]  Moshe Oren,et al.  Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia , 1985, Nature.

[16]  W. Nauseef.  Myeloperoxidase biosynthesis by a human promyelocytic leukemia cell line: insight into myeloperoxidase deficiency. , 1986, Blood.

[17]  J. Rowley,et al.  Further evidence for a non‐random chromosomal abnormality in acute promyelocytic leukemia , 1977, International journal of cancer.

[18]  M. Isobe,et al.  The human gene encoding GM-CSF is at 5q21-q32, the chromosome region deleted in the 5q- anomaly. , 1985, Science.